Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytogen Submits IND for Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Cytogen Submits IND for Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cytogen Corp. submitted an IND application to the FDA for CYT-500, the company’s lead therapeutic candidate targeting prostate-specific membrane antigen (PSMA). Subject to FDA acceptance and Institutional Review Board (IRB) approval at the planned clinical site, Cytogen expects to begin the first U.S. Phase I trial of CYT-500 in patients with hormone-refractory prostate cancer.

CYT-500 incorporates the same monoclonal antibody utilized in Cytogen’s Prostascint molecular imaging agent, but is linked to a therapeutic as opposed to an imaging payload. This novel product candidate is designed to enable targeted delivery of a cytotoxic agent to PSMA-expressing cells. Cytogen retains full and exclusive development rights to CYT-500.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters